CervoMed (STU:DP8) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is CervoMed Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CervoMed's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CervoMed could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for CervoMed's Cash-to-Debt or its related term are showing as below:

STU:DP8' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33 Med: 128.14 Max: No Debt
Current: No Debt

During the past 13 years, CervoMed's highest Cash to Debt Ratio was No Debt. The lowest was 0.33. And the median was 128.14.

STU:DP8's Cash-to-Debt is ranked better than
99.87% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs STU:DP8: No Debt

CervoMed Cash-to-Debt Historical Data

The historical data trend for CervoMed's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CervoMed Cash-to-Debt Chart

CervoMed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

57.47

123.74

No Debt

0.33

No Debt

CervoMed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of CervoMed's Cash-to-Debt

For the Biotechnology subindustry, CervoMed's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CervoMed's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CervoMed's Cash-to-Debt falls into.

CervoMed Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CervoMed's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

CervoMed had no debt ⁽¹⁾.

CervoMed's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

CervoMed had no debt ⁽¹⁾.

CervoMed (STU:DP8) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CervoMed Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CervoMed's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CervoMed (STU:DP8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (STU:DP8) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CRVO:USA

Address

20 Park Plaza, Suite 424, Boston, MA, USA, 02216

Website

https://www.diffusionpharma.com

CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.

CervoMed (STU:DP8) Headlines

No Headlines

CervoMed (STU:DP8) Cash-to-Debt : No Debt (1) (As of Mar. 2024)